Alpine Immune Sciences (NASDAQ:ALPN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

A number of other equities research analysts have also recently weighed in on ALPN. Piper Jaffray Companies started coverage on Alpine Immune Sciences in a research note on Thursday, September 27th. They issued an “overweight” rating and a $12.00 price objective for the company. ValuEngine raised Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. Finally, Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the company a “buy” rating in a report on Monday, November 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $12.67.

Shares of NASDAQ ALPN traded up $0.27 during midday trading on Friday, reaching $5.25. 100 shares of the stock were exchanged, compared to its average volume of 16,314. Alpine Immune Sciences has a twelve month low of $3.66 and a twelve month high of $11.68. The stock has a market capitalization of $66.18 million, a price-to-earnings ratio of -4.38 and a beta of 1.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.20 and a quick ratio of 9.20.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 43.25%. Analysts anticipate that Alpine Immune Sciences will post -2.62 earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in Alpine Immune Sciences by 122.2% in the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 18,052 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Alpine Immune Sciences by 20.9% in the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after purchasing an additional 21,124 shares during the last quarter. Vanguard Group Inc grew its holdings in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 11,200 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 11,200 shares during the last quarter. 54.74% of the stock is currently owned by institutional investors and hedge funds.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Recommended Story: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.